The HSP90 Inhibitor 17-AAG Exhibits Potent Antitumor Activity for Pheochromocytoma in a Xenograft Model

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Feb 16

PMID 25682284

Citations 3

Authors

Yunze Xu

Qi Zhu

Dongning Chen

Zhoujun Shen

Weiqing Wang

Guang Ning

Yu Zhu

Affiliations

Soon will be listed here.

Abstract

This study aims to investigate the effect of heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in the malignant pheochromocytoma using a xenograft mouse model. Treatment with 17-AAG induced a marked reduction in the volume and weight of PC12 pheochromocytoma cell tumor xenografts in mice. Furthermore, 17-AAG also significantly inhibited the expression of HSP90 and its client proteins. Our results validated HSP90 as an important target in pheochromocytoma and provided rationale for the testing of HSP90 inhibitors as a promising therapeutic agent in the antitumor therapy of pheochromocytoma.

Citing Articles

Esterase-Responsive Polyglycerol-Based Nanogels for Intracellular Drug Delivery in Rare Gastrointestinal Stromal Tumors.

Schotz S, Griepe A, Goerisch B, Kortam S, Shammai Vainer Y, Dimde M Pharmaceuticals (Basel). 2023; 16(11).

PMID: 38004483 PMC: 10675119. DOI: 10.3390/ph16111618.

Heat shock protein 90α couples with the MAPK-signaling pathway to determine meiotic maturation of porcine oocytes.

Liu Y, Liu X, Wang P, Yu X, Miao J, Liu S J Anim Sci. 2018; 96(8):3358-3369.

PMID: 29800308 PMC: 6095267. DOI: 10.1093/jas/sky213.

Effects of salinomycin and 17‑AAG on proliferation of human gastric cancer cells in vitro.

Zhang Z, Zhao J, Mi Z, Pang Q, Wang A, Chen M Mol Med Rep. 2017; 16(2):1063-1070.

PMID: 28627587 PMC: 5562019. DOI: 10.3892/mmr.2017.6735.

References

Pacey S, Gore M, Chao D, Banerji U, Larkin J, Sarker S . A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Invest New Drugs. 2010; 30(1):341-9. DOI: 10.1007/s10637-010-9493-4. View

Xu Y, Zhang C, Chen D, Zhao J, Shen Z, Wu Y . Effect of HSP90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation. Tumour Biol. 2013; 34(6):4065-71. DOI: 10.1007/s13277-013-0996-4. View

Trepel J, Mollapour M, Giaccone G, Neckers L . Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010; 10(8):537-49. PMC: 6778733. DOI: 10.1038/nrc2887. View

Lang S, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke M . Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther. 2007; 6(3):1123-32. DOI: 10.1158/1535-7163.MCT-06-0628. View

Whitesell L, Lindquist S . HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005; 5(10):761-72. DOI: 10.1038/nrc1716. View

Khong T, Spencer A . Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma. Mol Cancer Ther. 2011; 10(10):1909-17. DOI: 10.1158/1535-7163.MCT-11-0174. View

Giubellino A, Sourbier C, Lee M, Scroggins B, Bullova P, Landau M . Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma. PLoS One. 2013; 8(2):e56083. PMC: 3573066. DOI: 10.1371/journal.pone.0056083. View

Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm M, Fritz L . A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003; 425(6956):407-10. DOI: 10.1038/nature01913. View

Eiseman J, Lan J, Lagattuta T, Hamburger D, Joseph E, Covey J . Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts. Cancer Chemother Pharmacol. 2004; 55(1):21-32. DOI: 10.1007/s00280-004-0865-3. View

10.

Moulick K, Ahn J, Zong H, Rodina A, Cerchietti L, Gomes DaGama E . Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol. 2011; 7(11):818-26. PMC: 3265389. DOI: 10.1038/nchembio.670. View

11.

Sanderson S, Valenti M, Gowan S, Patterson L, Ahmad Z, Workman P . Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther. 2006; 5(3):522-32. DOI: 10.1158/1535-7163.MCT-05-0439. View

12.

Ayala-Ramirez M, Feng L, Johnson M, Ejaz S, Habra M, Rich T . Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab. 2010; 96(3):717-25. DOI: 10.1210/jc.2010-1946. View

13.

Gartner E, Silverman P, Simon M, Flaherty L, Abrams J, Ivy P . A phase II study of 17-allylamino-17-demethoxygeldanamycin in metastatic or locally advanced, unresectable breast cancer. Breast Cancer Res Treat. 2011; 131(3):933-7. PMC: 3839045. DOI: 10.1007/s10549-011-1866-7. View

14.

Adler J, Meyer-Rochow G, Chen H, Benn D, Robinson B, Sippel R . Pheochromocytoma: current approaches and future directions. Oncologist. 2008; 13(7):779-93. DOI: 10.1634/theoncologist.2008-0043. View

15.

Iyer G, Morris M, Rathkopf D, Slovin S, Steers M, Larson S . A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol. 2011; 69(4):1089-97. PMC: 3471133. DOI: 10.1007/s00280-011-1789-3. View

16.

Powers M, Workman P . Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer. 2007; 13 Suppl 1:S125-35. DOI: 10.1677/erc.1.01324. View